Overview

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Status:
Completed
Trial end date:
2020-10-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Valsartan